What Referring Physicians Need to Know About Current Peripheral Artery Disease Guidelines
-
By
-
June 22, 2026
-
4 min
By
June 22, 2026
by
June 22, 2026
Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.
June 16, 2026
Application supported by Phase 3 smoking-cessation data and long-term safety findings.
June 22, 2026